Success Story: Amplifying the Patient Voice in Myeloma Screening — Perluvinir and the iStopMM Trial September 8, 2026 The iStopMM trial (Iceland Screens, Treats, or Prevents Multiple Myeloma) — a population-based randomized clinical trial screening for monoclonal gammopathy of undetermined significance (MGUS) — places patients at the heart of how research is designed, delivered, and […]
Success Story: Patients at the Forefront of DCIS De‑Escalation Through the LORD Trial May 18, 2026 The LORD trial (LOw Risk Ductal carcinoma in situ – DCIS) – a landmark international study that places patients at the center of research design, decision-making, and dissemination was developed through close collaboration between researchers and patient advocates. The LORD trial demonstrates how meaningful patient partnership can reshape clinical research and improve relevance, feasibility, and impact. The
Success Story: Patients at the Forefront of DCIS De‑Escalation Through the LORD Trial Read More »
Amplifying Patient Voice: Success Story March 27, 2026 Showcasing Outstanding Patient Partnership in the HYPERION CCA Study We are delighted to spotlight the partnership between HYPERION CCA research team, and the Cholangiocarcinoma Foundation (CCF). The HYPERION CCA study is led by Dr. Eugene Koay at The University of Texas MD Anderson Cancer Center, one of our grantees. This research team
Amplifying Patient Voice: Success Story Read More »
Grantee Spotlight: Developing New Immune-Based Treatments for Aggressive Brain Cancer March 24, 2026 The Challenge Malignant brain tumors, such as glioblastoma, are among the most aggressive cancers in adults. Despite maximal standard therapy – surgery followed by radiotherapy and temozolomide chemotherapy – most patients live only about 15 to 16 months after diagnosis. For decades, progress has been slow, and new treatment approaches are
Grantee Spotlight: Developing New ImmuneBased Treatments for Aggressive Brain Cancer Read More »
